Y-Intercept (HK)’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,536
| Closed | -$343K | – | 1687 |
|
|
2026
Q1 | $343K | Sell |
8,536
-23,045
| -73% | -$497K | 0.01% | 1348 |
|
|
2025
Q4 | $793K | Sell |
31,581
-132,232
| -81% | -$3.1M | 0.02% | 1083 |
|
|
2025
Q3 | $3.71M | Sell |
163,813
-462
| -0.3% | -$10.8K | 0.09% | 317 |
|
|
2025
Q2 | $2.84M | Buy |
164,275
+134,698
| +455% | +$2.49M | 0.07% | 443 |
|
|
2025
Q1 | $647K | Buy |
+29,577
| New | +$817K | 0.04% | 591 |
|
|
2024
Q3 | – | Sell |
-60,522
| Closed | -$2.32M | – | 1284 |
|
|
2024
Q2 | $2.32M | Buy |
+60,522
| New | +$2.74M | 0.13% | 211 |
|
|
2024
Q1 | – | Sell |
-15,008
| Closed | -$898K | – | 1340 |
|
|
2023
Q4 | $898K | Buy |
+15,008
| New | +$761K | 0.08% | 352 |
|
|
2023
Q3 | – | Sell |
-11,595
| Closed | -$1.06M | – | 1038 |
|
|
2023
Q2 | $1.06M | Buy |
11,595
+6,019
| +108% | +$519K | 0.11% | 269 |
|
|
2023
Q1 | $368K | Buy |
+5,576
| New | +$322K | 0.04% | 677 |
|
|
2022
Q2 | – | Sell |
-4,363
| Closed | -$222K | – | 845 |
|
|
2022
Q1 | $222K | Buy |
+4,363
| New | +$193K | 0.05% | 574 |
|
Other funds holding APLS
Y-Intercept (HK)'s APLS Position: Q2 2026 in Review
Y-Intercept (HK) sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 8,536 shares — an estimated $343K sold.
Y-Intercept (HK) first reported a position in APLS in Q1 2022 and held it in 10 quarters. The position peaked at $3.71M in Q3 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Y-Intercept (HK) reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Y-Intercept (HK) sold 8,536 Apellis Pharmaceuticals shares in Q2 2026, an estimated $343K.
- Y-Intercept (HK) first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 10 quarters.
- Y-Intercept (HK)'s Apellis Pharmaceuticals position peaked at $3.71M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.